Reduction of intraocular pressure (IOP) by pharmaceutical or surgical means has long been
the standard treatment for glaucoma. A number of excellent drugs are available that are …

Introduction: It is generally believed that topical administration of eye drops safeguards
against harmful systemic effects. However, about 80% of the drug in the ophthalmic products …

Diabetic foot ulcers are a major health care concern with limited effective therapies.
Mesenchymal stem cell (MSC)-based therapies are promising treatment options due to their …

Timolol maleate is a non‐selective β‐adrenoceptor antagonist currently used mainly as an
ocular preparation for the treatment of glaucoma and ocular hypertension. Despite the …

Glaucoma is a progressive, chronic optic neuropathy characterized by a typical visual field
defects. Four main classes of topical medication are actually available on the market: beta …

The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and
the emerging potential of preservative-free (PF) DTFC are reviewed with published evidence …

The increment in ocular drug bioavailability after topical administration is one of the main
challenges in pharmaceutical technology. For several years, different strategies based on …

It is estimated that 2.2 million people have glaucoma in the US and 67 million people
worldwide. The majority of cases are associated with elevated intraocular pressure (IOP) …

Timolol has mainly been used topically for the treatment of glaucoma. It has been suggested
that the drug is metabolized by cytochrome P450 CYP2D6. The matter has not, however …

A woman with ocular hypertension suffered from severe bradycardia, hypotension and
syncope attacks in temporal relation with ophthalmic timolol application. Topically applied …